VialWatch Subscribe — free

Sample issue

Here's what your inbox looks like every Monday at 6 AM.

A representative VialWatch Weekly Brief — free for all subscribers. Below is a rendered preview of the actual email format, with sample data drawn from a real recent week of FDA shortage activity.

VialWatch Weekly Brief
Sample issue

4 new shortages this week, 2 relief signals, 1 Class II recall.

New
4
shortages
Resolved
3
drugs back
Relief
2
new ANDAs
Quality
1
recall
Lead story · Watch closely

Piperacillin/Tazobactam: Class II recall narrows an already strained market

A voluntary Class II recall on three lots of Piperacillin/Tazobactam 3.375g and 4.5g vials was initiated this week, citing particulate matter. With Pfizer and Sandoz already reporting allocation, this leaves 3 manufacturers with current supply for U.S. hospital systems.

Affected NDCs: 55150-242-XX, 55150-243-XX, 55150-247-XX (lot numbers in linked FDA enforcement notice).

New shortages this week

Sodium Chloride 0.9% — 1L IV bags
Reported Apr 23
Manufacturing delay reported by primary supplier. Two alternate manufacturers continue normal supply.
Magnesium Sulfate — 50% injection
Reported Apr 22
Increased demand reported. One alternate manufacturer reporting partial supply.
Hydromorphone HCl — 2mg/mL injection
Reported Apr 21
DEA quota issue at one manufacturer. Three other manufacturers actively supplying.

Relief signals

Cefazolin — new ANDA approval
FDA-approved on April 18. Commercial supply typically appears within 8–12 weeks. Estimated relief: late June.
Norepinephrine Bitartrate — 2 ANDA filings under review
Two pending applications now under FDA review. Approval timing not yet disclosed but a positive forward indicator for a long-running shortage.

Resolved this week

  • Vancomycin HCl — all presentations restored
  • Furosemide 10mg/mL injection — back to full allocation
  • Dextrose 50% prefilled syringes — normal supply resumed
VialWatch Pro

Pro subscribers also got this week:

  • Vetted alternative-supplier shortlist for Piperacillin/Tazobactam
  • Same-day push alerts on the recall (8 hours ahead of trade press)
  • Custom watchlist tied to your formulary
  • Decision-ready briefs per shortage with recommended next steps
Try Pro free for 14 days →
$149/mo · cancel anytime · no card required for trial
About this brief: VialWatch aggregates and analyzes data from FDA Drug Shortages and other public regulatory sources. Informational only — not medical, regulatory, or procurement advice.
Get the real brief every Monday — free

No credit card. Unsubscribe anytime in one click.